Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

sanofi-aventis Pakistan

KASE:SAPL
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SAPL
KASE
PKR7B
Market Cap
  1. Home
  2. PK
  3. Pharmaceuticals & Biotech
Company description

sanofi-aventis Pakistan Limited manufactures and sells pharmaceuticals, consumer healthcare products, and vaccines primarily in Pakistan. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
SAPL Share Price and Events
7 Day Returns
0%
KASE:SAPL
-6.4%
PK Pharmaceuticals
-7.8%
PK Market
1 Year Returns
-13.6%
KASE:SAPL
-21.6%
PK Pharmaceuticals
-32.3%
PK Market
SAPL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
sanofi-aventis Pakistan (SAPL) 0% 14.3% -13.2% -13.6% -64.1% 15.2%
PK Pharmaceuticals -6.4% -10.3% -16.7% -21.6% -55.8% -16.2%
PK Market -7.8% -23.8% -31% -32.3% -47% -28.1%
1 Year Return vs Industry and Market
  • SAPL outperformed the Pharmaceuticals industry which returned -21.6% over the past year.
  • SAPL outperformed the Market in Pakistan which returned -32.3% over the past year.
Price Volatility
SAPL
Industry
5yr Volatility vs Market

SAPL Value

 Is sanofi-aventis Pakistan undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of sanofi-aventis Pakistan to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for sanofi-aventis Pakistan.

KASE:SAPL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-12-31) in PKR PKR 8.000000
Payout Ratio Company Filings (2019-12-31) 2490.9%
Discount Rate (Cost of Equity) See below 22.5%
Perpetual Growth Rate 10-Year PK Government Bond Rate 11.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for KASE:SAPL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year PK Govt Bond Rate 11.4%
Equity Risk Premium S&P Global 13.7%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.691 (1 + (1- 30%) (11.55%))
0.813
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 11.38% + (0.813 * 13.68%)
22.5%

Discounted Cash Flow Calculation for KASE:SAPL using Dividend Discount Model Model

The calculations below outline how an intrinsic value for sanofi-aventis Pakistan is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

KASE:SAPL Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= PKR8 / (22.5% - 11.38%)
PKR71.91
KASE:SAPL Discount to Share Price
Calculation Result
Value per share (PKR) From above. PKR71.91
Current discount Discount to share price of PKR720.00
= -1 x (PKR720.00 - PKR71.91) / PKR71.91
-901.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of sanofi-aventis Pakistan is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for sanofi-aventis Pakistan's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are sanofi-aventis Pakistan's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
KASE:SAPL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in PKR PKR16.05
KASE:SAPL Share Price ** KASE (2020-03-27) in PKR PKR720
Pakistan Pharmaceuticals Industry PE Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 16.63x
Pakistan Market PE Ratio Median Figure of 275 Publicly-Listed Companies 6.94x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of sanofi-aventis Pakistan.

KASE:SAPL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= KASE:SAPL Share Price ÷ EPS (both in PKR)

= 720 ÷ 16.05

44.86x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • sanofi-aventis Pakistan is overvalued based on earnings compared to the PK Pharmaceuticals industry average.
  • sanofi-aventis Pakistan is overvalued based on earnings compared to the Pakistan market.
Price based on expected Growth
Does sanofi-aventis Pakistan's expected growth come at a high price?
Raw Data
KASE:SAPL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 44.86x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Asia Pharmaceuticals Industry PEG Ratio Median Figure of 157 Publicly-Listed Pharmaceuticals Companies 1.37x
Pakistan Market PEG Ratio Median Figure of 28 Publicly-Listed Companies 0.38x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for sanofi-aventis Pakistan, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on sanofi-aventis Pakistan's assets?
Raw Data
KASE:SAPL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in PKR PKR412.68
KASE:SAPL Share Price * KASE (2020-03-27) in PKR PKR720
Pakistan Pharmaceuticals Industry PB Ratio Median Figure of 8 Publicly-Listed Pharmaceuticals Companies 2.29x
Pakistan Market PB Ratio Median Figure of 387 Publicly-Listed Companies 0.55x
KASE:SAPL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= KASE:SAPL Share Price ÷ Book Value per Share (both in PKR)

= 720 ÷ 412.68

1.74x

* Primary Listing of sanofi-aventis Pakistan.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • sanofi-aventis Pakistan is good value based on assets compared to the PK Pharmaceuticals industry average.
X
Value checks
We assess sanofi-aventis Pakistan's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. sanofi-aventis Pakistan has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SAPL Future Performance

 How is sanofi-aventis Pakistan expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as sanofi-aventis Pakistan has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.3%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is sanofi-aventis Pakistan expected to grow at an attractive rate?
  • Unable to compare sanofi-aventis Pakistan's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare sanofi-aventis Pakistan's earnings growth to the Pakistan market average as no estimate data is available.
  • Unable to compare sanofi-aventis Pakistan's revenue growth to the Pakistan market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
KASE:SAPL Future Growth Rates Data Sources
Data Point Source Value (per year)
Asia Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.3%
Asia Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 10.7%
Pakistan Market Earnings Growth Rate Market Cap Weighted Average 15.2%
Pakistan Market Revenue Growth Rate Market Cap Weighted Average 7.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
KASE:SAPL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in PKR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
KASE:SAPL Past Financials Data
Date (Data in PKR Millions) Revenue Cash Flow Net Income *
2019-12-31 14,501 155
2019-09-30 13,763 -46 -27
2019-06-30 13,434 -139 -62
2019-03-31 13,232 410 467
2018-12-31 12,961 1,248 613
2018-09-30 12,777 246 647
2018-06-30 12,587 632 998
2018-03-31 12,728 1,383 963
2017-12-31 12,446 1,329 1,006
2017-09-30 12,210 2,601 1,360
2017-06-30 12,804 2,652 1,389
2017-03-31 12,279 1,809 1,306

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if sanofi-aventis Pakistan is high growth as no earnings estimate data is available.
  • Unable to determine if sanofi-aventis Pakistan is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
KASE:SAPL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from sanofi-aventis Pakistan Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KASE:SAPL Past Financials Data
Date (Data in PKR Millions) EPS *
2019-12-31 16.05
2019-09-30 -2.77
2019-06-30 -6.42
2019-03-31 48.40
2018-12-31 63.54
2018-09-30 67.11
2018-06-30 103.45
2018-03-31 99.89
2017-12-31 104.32
2017-09-30 140.96
2017-06-30 144.01
2017-03-31 135.38

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if sanofi-aventis Pakistan will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine sanofi-aventis Pakistan's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. sanofi-aventis Pakistan's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess sanofi-aventis Pakistan's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
sanofi-aventis Pakistan has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SAPL Past Performance

  How has sanofi-aventis Pakistan performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare sanofi-aventis Pakistan's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • sanofi-aventis Pakistan's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • sanofi-aventis Pakistan's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • sanofi-aventis Pakistan's 1-year earnings growth is negative, it can't be compared to the PK Pharmaceuticals industry average.
Earnings and Revenue History
sanofi-aventis Pakistan's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from sanofi-aventis Pakistan Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KASE:SAPL Past Revenue, Cash Flow and Net Income Data
Date (Data in PKR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 14,500.68 154.84 2,848.25
2019-09-30 13,762.97 -26.70 2,736.66
2019-06-30 13,433.60 -61.97 2,749.59
2019-03-31 13,232.19 466.84 2,631.57
2018-12-31 12,960.84 612.79 2,588.63
2018-09-30 12,777.12 647.27 2,616.54
2018-06-30 12,586.82 997.74 2,511.87
2018-03-31 12,727.67 963.32 2,558.75
2017-12-31 12,446.05 1,006.12 2,495.48
2017-09-30 12,209.60 1,359.58 2,473.85
2017-06-30 12,803.75 1,388.98 2,400.71
2017-03-31 12,278.77 1,305.89 2,407.60
2016-12-31 11,890.24 1,018.92 2,393.88
2016-09-30 11,906.22 564.21 2,502.51
2016-06-30 11,075.04 190.39 2,590.11
2016-03-31 11,192.10 -41.39 2,525.66
2015-12-31 10,785.88 66.48 2,464.64
2015-09-30 10,628.41 250.52 2,325.87
2015-06-30 10,424.84 327.64 2,224.26
2015-03-31 9,936.94 293.89 2,164.17
2014-12-31 9,949.46 238.47 2,093.08
2014-09-30 9,724.65 273.88 1,942.38
2014-06-30 9,307.30 243.26 1,898.84
2014-03-31 9,165.50 368.68 1,786.41
2013-12-31 8,791.59 309.83 1,695.49
2013-09-30 9,002.31 395.87 1,748.19
2013-06-30 8,821.39 518.12 1,722.87
2013-03-31 8,590.30 494.79 1,746.32

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • sanofi-aventis Pakistan has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • sanofi-aventis Pakistan used its assets less efficiently than the PK Pharmaceuticals industry average last year based on Return on Assets.
  • sanofi-aventis Pakistan's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess sanofi-aventis Pakistan's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
sanofi-aventis Pakistan has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SAPL Health

 How is sanofi-aventis Pakistan's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up sanofi-aventis Pakistan's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • sanofi-aventis Pakistan is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • sanofi-aventis Pakistan's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of sanofi-aventis Pakistan's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 7.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from sanofi-aventis Pakistan Company Filings, last reported 2 months ago.

KASE:SAPL Past Debt and Equity Data
Date (Data in PKR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 3,981.31 802.15 42.85
2019-09-30 3,981.31 798.83 42.85
2019-06-30 3,953.63 766.31 51.02
2019-03-31 4,426.12 300.20 46.08
2018-12-31 4,297.67 0.00 254.65
2018-09-30 4,321.10 105.50 58.12
2018-06-30 4,331.94 77.68 135.09
2018-03-31 4,425.39 39.85 157.66
2017-12-31 4,148.62 271.30 15.84
2017-09-30 4,092.12 0.00 348.59
2017-06-30 3,749.29 184.15 286.90
2017-03-31 3,732.91 838.05 48.56
2016-12-31 3,412.34 1,175.44 50.44
2016-09-30 3,007.57 1,883.20 95.75
2016-06-30 2,637.07 2,191.01 80.94
2016-03-31 2,437.82 2,455.41 46.46
2015-12-31 2,410.03 2,852.88 25.48
2015-09-30 2,451.88 3,079.12 39.48
2015-06-30 2,452.02 3,340.03 18.07
2015-03-31 2,528.49 3,682.88 26.24
2014-12-31 2,392.15 3,248.87 9.28
2014-09-30 2,255.06 2,611.51 16.64
2014-06-30 2,177.93 2,181.25 29.10
2014-03-31 2,310.54 2,156.22 17.62
2013-12-31 2,226.61 2,480.86 21.93
2013-09-30 2,054.50 2,663.06 23.56
2013-06-30 1,999.79 2,056.92 16.50
2013-03-31 2,038.36 1,926.71 22.10
  • sanofi-aventis Pakistan's level of debt (20.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (135.9% vs 20.1% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Interest payments on debt are well covered by earnings (EBIT is 8.5x coverage).
X
Financial health checks
We assess sanofi-aventis Pakistan's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. sanofi-aventis Pakistan has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SAPL Dividends

 What is sanofi-aventis Pakistan's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.11%
Current annual income from sanofi-aventis Pakistan dividends.
If you bought PKR2,000 of sanofi-aventis Pakistan shares you are expected to receive PKR22 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • sanofi-aventis Pakistan's pays a lower dividend yield than the bottom 25% of dividend payers in Pakistan (2.78%).
  • sanofi-aventis Pakistan's dividend is below the markets top 25% of dividend payers in Pakistan (10.03%).
Upcoming dividend payment

Purchase sanofi-aventis Pakistan before the 'Ex-dividend' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
KASE:SAPL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Pakistan Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 3.1%
Pakistan Market Average Dividend Yield Market Cap Weighted Average of 214 Stocks 8%
Pakistan Minimum Threshold Dividend Yield 10th Percentile 1.7%
Pakistan Bottom 25% Dividend Yield 25th Percentile 2.8%
Pakistan Top 25% Dividend Yield 75th Percentile 10%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

KASE:SAPL Past Annualized Dividends Data
Date (Data in PKR) Dividend per share (annual) Avg. Yield (%)
2020-03-03 8.000 1.081
2019-03-14 30.000 4.796
2019-03-01 30.000 3.487
2018-04-03 45.000 4.673
2018-03-07 45.000 3.343
2017-03-08 30.000 1.765
2016-04-01 3.000 0.300
2016-02-25 3.000 0.614
2015-03-12 7.000 1.079
2014-02-26 10.000 1.285
2013-02-27 12.500 2.414
2012-04-05 10.000 4.516
2011-02-11 10.000 6.754
2009-12-31 7.000 5.069

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • sanofi-aventis Pakistan is not paying a notable dividend for Pakistan, therefore no need to check if the payments are stable.
  • sanofi-aventis Pakistan is not paying a notable dividend for Pakistan, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of sanofi-aventis Pakistan's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of sanofi-aventis Pakistan's dividends as it is not paying a notable one for Pakistan.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess sanofi-aventis Pakistan's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.7%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can sanofi-aventis Pakistan afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. sanofi-aventis Pakistan has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SAPL Management

 What is the CEO of sanofi-aventis Pakistan's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Asim Jamal
CEO Bio

Dr. Asim Jamal has been the Chief Executive Officer, Managing Director and Executive Director of Sanofi Aventis Pakistan Limited since June 1, 2015. Dr. Jamal served as a Director of Business Development & Excellence at Sanofi Aventis Pakistan Limited.

CEO Compensation
  • Insufficient data for Asim to compare compensation growth.
  • Insufficient data for Asim to establish whether their remuneration is reasonable compared to companies of similar size in .
Management Team

Asim Jamal

TITLE
CEO & Executive Director

Yasser Pirmuhammad

TITLE
CFO & Executive Director

Saiyed Raza

TITLE
Head of Business Operations

Shakeel Mapara

TITLE
Director of Human Resources

Laila Khan

TITLE
Head of External Affairs

Zubair-Ul-Hasan Rizvi

TITLE
Director of Diabetes Business Unit

Aamer Waheed

TITLE
Head of Trade & Revenue Management

Syed Hasani

TITLE
Director of Industrial Affairs

Munawar Uqaili

TITLE
Head of Vaccines Business

Syed Iqbal

TITLE
Head of Business Unit - Classic
Board of Directors Tenure

Average tenure of the sanofi-aventis Pakistan board of directors in years:

4.2
Average Tenure
  • The tenure for the sanofi-aventis Pakistan board of directors is about average.
Board of Directors

Syed Ali

TITLE
Chairman

Asim Jamal

TITLE
CEO & Executive Director
TENURE
4.8 yrs

Yasser Pirmuhammad

TITLE
CFO & Executive Director
TENURE
4.2 yrs

Laila Khan

TITLE
Head of External Affairs

Syed Hasani

TITLE
Director of Industrial Affairs

Arshad Gohar

TITLE
Non-Executive Director
TENURE
9 yrs

Syed Ali

TITLE
Non-Executive Director
TENURE
33 yrs

Ana Arcos

TITLE
Non-Executive Director
TENURE
2.9 yrs

Thomas Rouckout

TITLE
Non-Executive Director
AGE
42
TENURE
2.9 yrs

Imtiaz Husain Laliwala

TITLE
Independent Director
TENURE
2.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (PKR) Value (PKR)
X
Management checks
We assess sanofi-aventis Pakistan's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. sanofi-aventis Pakistan has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SAPL News

Simply Wall St News

SAPL Company Info

Description

sanofi-aventis Pakistan Limited manufactures and sells pharmaceuticals, consumer healthcare products, and vaccines primarily in Pakistan. It offers products for diabetics that include oral products under the Amaryl, Daonil, and Neodipar names, as well as insulins under the Lantus and Apidra names; medicines for cancer under the Jevtana, Taxotere, and Eloxatin names; urology products under the Renvela, Thymoglobulin, and Xatral names; and pain management products under the No-Spa, Muscoril, and Stemetil. The company also provides products for allergy management under the Telfast, Telfast-D, Avil, Nasacort, Phenergan, and Tixylix names; products for sleep disorders under the Tixylix name; products for emergency care under the Haemaccel name; and cardiology products under the Plavix, CoPlavix, Aprovel, CoAprovel, Cordarone, Clexane, Tritace, CoTritace, Winstor, and Lasix/ Lasoride names. In addition, it offers antibiotic products under the Tarivid, Claforan, Aventriax, Orelox, Tavanic, and Targocid names; anti-diarrheals under the Flagyl, SECNIDAL FORTE, and Enterogermina names; products for epilepsy under the Frisium; and consumer healthcare products under the Selsun Blue and CollaFlex names. The company was formerly known as Aventis Limited and changed its name to sanofi-aventis Pakistan Limited in September 2005. sanofi-aventis Pakistan Limited was incorporated in 1967 and is headquartered in Karachi, Pakistan. sanofi-aventis Pakistan Limited is a subsidiary of Sanofi Foreign Participations B.V.

Details
Name: sanofi-aventis Pakistan Limited
SAPL
Exchange: KASE
Founded: 1967
PKR6,944,256,000
9,644,800
Website: http://www.sanofi.com.pk
Address: sanofi-aventis Pakistan Limited
Plot 23,
Korangi industrial Area,
Karachi,
74900,
Pakistan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
KASE SAPL Ordinary Shares Pakistan Stock Exchange Limited PK PKR 11. Nov 1992
Number of employees
Current staff
Staff numbers
941
sanofi-aventis Pakistan employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/29 15:01
End of day share price update: 2020/03/27 00:00
Last earnings filing: 2020/03/03
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.